Charles Li Xiaojia, chief executive of bourse operator Hong Kong Exchanges and Cleating, at the Biotech summit last week. Photo: Edward Wong

Reward and risk: the two faces of Hong Kong’s new listing rules for biotech firms

Allowing biotech firms to list in the city before they generate revenue is a bonus for the firms, but investors need to be aware of the pitfalls

Topic |   Pharmaceuticals

TOP PICKS

Charles Li Xiaojia, chief executive of bourse operator Hong Kong Exchanges and Cleating, at the Biotech summit last week. Photo: Edward Wong
READ FULL ARTICLE